Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Inc. - Common Stock (NQ: IXHL )

2.940 +0.170 (+6.14%)
Streaming Delayed Price Updated: 3:56 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. 
Via Talk Markets
All 5 Cannabis Categories Down Last Week; Only 1 Is UP YTD
The 5 categories in the cannabis sector perform quite differently from each other. Only 1 is up YTD. 
Via Talk Markets
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use 
Via News Direct
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
Incannex Healthcare Ltd (ASX:IHL NASDAQ:IXHL) CEO and MD Joel Latham sits down with Proactive to talk about the development and manufacturing deal it has struck with pharma giant Catalent to produce... 
Via TheNewswire.com
Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has... 
Via Benzinga
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients... 
Via TheNewswire.com
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial 
Via News Direct
Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a... 
Via Benzinga
Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results
Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ: 
Via Benzinga
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the biggest pre-market stock movers that traders will want to watch on Thursday! 
Via InvestorPlace
Incannex Files A Provisional Patent Application Of Its THC-Based IHL-42X For The Treatment Of Obstructive Sleep Apnea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of obstructive sleep apnea (‘OSA’). 
Via Benzinga
Eurofins To Produce Incannex' 2 CBD Medicated Chews For Treatment Of Nicotine And Opioid Addiction Disorders
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has engaged multinational contract development and manufacturing organization Eurofins Scientific (OTCPK:ERFSF) to manufacture Incannex’s two... 
Via Benzinga
Incannex Initiates BA/BE Clinical Trial Evaluating IHL-42X In Obstructive Sleep Apnoea
Cannabis and psychedelics-focused Pharma company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1... 
Via Benzinga
A Global List Of Cannabis Operators And Executives To Keep An Eye On In 2022 And Beyond
Less than 30 years after Israel became the first nation in the world to allow its citizens to use cannabis for medical purposes, the medical and adult-use cannabis markets have spread across the globe... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Incannex Healthcare (NASDAQ:IXHL) shares moved upwards by 30.7% to $5.19 during Friday's pre-market session. The market value of their outstanding shares is at $316.2 million. 
Via Benzinga
Australian Psychedelics: Incannex Business & Financials, New Research Center For Mushrooms & Eating Disorders
Clinical-stage biopharma company Incannex Healthcare Ltd. (NASDAQ: IXHL) shared its quarterly activities report and appendix 4C for the period ended 30 September 2022, noticeably applying for several... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investor! We're starting off Thursday with a breakdown of the biggest pre-market stock movers this morning! 
Via InvestorPlace
Unrivaled Brands & Other Cannabis Operators Just Made Some Key Executive Changes You Should Know About
As Benzinga Cannabis Capital Conference returns on September 13-14 to Chicago, gathering top CEOs, investors and leaders in the industry, let's scroll through the latest leadership changes within the... 
Via Benzinga
Icannex Taps Ex Pfizer, FDA & Regulatory Affairs Expert
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) appointed pharmaceutical executive Robert B. Clark to the board of directors. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Incannex Approved To Commence Phase 1 Clinical Trial Of CBD Based Anti-Inflammatory Drug
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary... 
Via Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.